Top

Critical Care

Published in:

01-06-2010 | Journal club critique

To JUPITER and beyond: Statins, inflammation, and primary prevention

Authors: Ajay D Rao, Eric B Milbrandt

Published in: Critical Care | Issue 3/2010

Excerpt

Evidence-Based Medicine Journal Club …

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359: 2195-2207. 10.1056/NEJMoa0807646CrossRefPubMed

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347: 1557-1565. 10.1056/NEJMoa021993CrossRefPubMed

Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344: 1959-1965. 10.1056/NEJM200106283442601CrossRefPubMed

Slejko J, Page RL, Sullivan PW: Statin therapy is cost-effective for vascular event prevention in adults with elevated C-reactive protein: Implications of JUPITER [abstract]. J Am Coll Cardiol 2010, 55: A131.E1229.CrossRef

Almog Y: Statins, inflammation, and sepsis: hypothesis. Chest 2003, 124: 740-743. 10.1378/chest.124.2.740CrossRefPubMed

Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K: Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000, 294: 1043-1046.PubMed

Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C: HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004, 109: 2560-2565. 10.1161/01.CIR.0000129774.09737.5BCrossRefPubMed

Merx MW, Liehn EA, Graf J, Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C: Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005, 112: 117-124. 10.1161/CIRCULATIONAHA.104.502195CrossRefPubMed

Kopterides P, Falagas ME: Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009, 15: 325-334. 10.1111/j.1469-0691.2009.02750.xCrossRefPubMed

10.

Statins in Sepsis Study (STATInS)[http://www.anzctr.org.au/ACTRN12607000028404.aspx]

11.

The influence of Statins on Blood Vessel Function in Severe Sepsis[http://www.anzctr.org.au/ACTRN12607000393459.aspx]

12.

Statins for the Early Treatment of Sepsis (SETS)[http://clinicaltrials.gov/show/NCT00528580]

13.

Simvastatin and severe Sepsis: a randomised controlled Trial (SimSepT)[http://www.controlled-trials.com/ISRCTN92093279]

14.

Hydroxymethylglutaryl-CoA reductase inhibition in Acute lung injury to Reduce Pulmonary oedema and inflammation (HARP)[http://www.controlled-trials.com/ISRCTN70127774]

15.

Randomised double-blind placebo-controlled trial of 40 mg/day of Atorvastatin on reduction in severity of SEPSIS in ward patients (ASEPSIS)[http://www.controlled-trials.com/ISRCTN64637517]

16.

Effect of Rosuvastatin in Abdominal Sepsis[http://clinicaltrials.gov/ct2/show/NCT00357123]

17.

Statin for Immunomudulation in Sepsis[http://clinicaltrials.gov/ct2/show/NCT00452608]

18.

Simvastatin in Patients With Septic Shock[http://clinicaltrials.gov/ct2/show/NCT00450840]

19.

Statin Therapy in the Treatment of Sepsis[http://clinicaltrials.gov/ct2/show/NCT00676897]

20.

Pravastatin and Ventilator Associated Pneumonia (EPRAVAP)[http://clinicaltrials.gov/ct2/show/NCT00702130]

21.

Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M: A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009, 35: 717-721. 10.1007/s00134-008-1358-3CrossRefPubMed

22.

Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177: 1242-1247. 10.1164/rccm.200712-1777OCPubMedCentralCrossRefPubMed

Title: To JUPITER and beyond: Statins, inflammation, and primary prevention
Authors: Ajay D Rao
Eric B Milbrandt
Publication date: 01-06-2010
Publisher: BioMed Central
Published in: Critical Care / Issue 3/2010
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc9006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

To JUPITER and beyond: Statins, inflammation, and primary prevention

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2010

Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts

Epinephrine: Is it really the black sheep of vasoactive agents?

Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators

Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008

Does proteolysis explain glutamine release from the septic brain?

Influenza and bacterial pneumonia - constant companions